[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
Last updated December 3, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

634.P2.28 Myeloproliferative Syndromes Poster III

Oral and Poster Abstracts
Poster Session
Monday, December 7, 2009: 6:00 PM-8:00 PM
Hall E (Ernest N. Morial Convention Center)
A Dynamic Prognostic Model to Predict Survival in Primary Myelofibrosis: a Study of the International Working Group for Myeloproliferative Neoplasm Research and Treatment (IWG-MRT)

Francesco Passamonti1*, Francisco Cervantes2*, Alessandro Vannucchi3*, Enrica Morra4*, Elisa Rumi1*, Arturo Pereira5*, Paola Guglielmelli3*, Ester Pungolino4*, Marianna Caramella4*, Cristiana Pascutto1*, Mario Lazzarino1*, Mario Cazzola1 and Ayalew Tefferi6

1Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
2Hematology Department, Hospital Clinic, Barcelona, Spain
3Department of Hematology, University of Florence, Florence, Italy
4Department of Hematology Oncology, Ospedale Niguarda, Milano, Italy
5Hematotherapy Department, Hospital Clinic, Barcelona, Spain
6Medicine, Division of Hematology, Mayo Clinic, Rochester, MN

A Novel, Highly Sensitive, Rapid, Non-PCR Based Method for the Detection of the JAK2V617F Mutation in Chronic Myeloproliferative Neoplasms

Giulia Minnucci1*, Giulia Amicarelli2*, Silvia Salmoiraghi3*, Orietta Spinelli, PhD3*, Daniel Adlerstein2* and Alessandro Rambaldi, MD3

1Università degli Studi di Milano Bicocca, Milano, Italy
2DiaSorin SpA, Nerviano (MI), Italy
3Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy

AML-1/RUNX-1 Is Overexpressed in Patients with Myeloproliferative Neoplasms and Mediates JAK2V617F-Independent Overexpression of NF-E2

Wei Wang*, Sven Schwemmers* and Heike L Pahl, Ph.D.

Department of Experimental Anaesthesiology, University Hospital Freiburg, Freiburg, Germany

Chronic Eosinophilic Leukaemia (CEL) with FIP1L1-PDGFRalpha Rearrangement (F/P): The Response to Imatinib (IM) Is Durable. A Report of 33 Patients with A Follow –up of 30 to 92 Months

Michela Rondoni1*, Emanuela Ottaviani2*, Daniela Cilloni, MD, PhD3, Pier Paolo Piccaluga4, Stefania Paolini5*, Ilaria Iacobucci, PhD6*, Simona Soverini, PhD7*, Serena Merante8*, Francesca Messa, PhD9*, Francesco Buccisano, M.D.10, Mario Tiribelli11*, Fabrizio Pane12*, Giuseppe Saglio13*, Francesco Lauria, MD14, Michele Baccarani, MD15 and Giovanni Martinelli, MD16*

1University of Siena, Department of Hematology and Transplants, Siena, Italy
2Haematology and Medical Oncology , University of Bologna, Italy
3Department of Clinical and Biological Sciences, University of Turin, Orbassano, Turin, Italy
4Department of Hematology and Oncology Sciences L. and A. Seràgnoli, University of Bologna, Italy
5Department of Hematology/Oncology L. and A. Seràgnoli, University of Bologna, Bologna, Italy
6Department of Hematology/Oncology, University of Bologna, Bologna, Italy
7Department of Hematology/Oncology, University of Bologna and S.Orsola - Malpighi Hospital, Bologna, Italy
8Hematology, San Matteo, Pavia, Italy
9Department of Clinical and Biological Sciences, University at Orbassano, Orbassano, Turin, Italy
10Hematology, University Tor Vergata, Roma, Italy
11Department of Medical and Morphological Researches, Division of Hematology and Bone Marrow Transplantation - AOU, Udine, Italy
12Department of Biochemistry and Medical Biotechnology, University of Naples, Naples, Italy
13Department of Clinical and Biological Sciences, University of Turin and San Luigi Hospital, Orbassano, Italy
14Hematology, University of Siena, Siena, Italy
15University of Bologna, S.Orsola Hospital, Bologna, Italy
16Department of Hematology and Science Oncology, University of Bologna, Bologna, Italy

Clinical Phenotype of Myeloproliferative Neoplasms with Activating CBL mutations Resembles Chronic Myelomonocytic Leukemia

Juliana Popa, MD1*, Susanne Schnittger, PhD2, Philipp Erben, MD1*, Tamara Weiss2*, Ayalew Tefferi, MD3, Eva M Kanders1*, Eva Lengfelder, MD1*, Martin C. Müller, MD1*, Torsten Haferlach, MD2, Andreas Hochhaus, MD4, Wolf-Karsten Hofmann, MD1* and Andreas Reiter, MD1*

1III. Medizinische Klinik, Universitaetsmedizin Mannheim, 68167 Mannheim, Germany
2MLL Munich Leukemia Laboratory, Munich, Germany
3Hematology, Mayo Clinic, Rochester, MN
4Universitätsklinikum Jena, Jena, Germany

Deranged MicroRNA 16-2 Expression Contributes to Erythropoiesis in Polycythemia Vera

Paola Guglielmelli, MD1*, Lorenzo Tozzi, BSc1*, Vanessa Ponziani, PhD1*, Elisa Bianchi, PhD2*, Ilaria Iacobucci, PhD3*, Betty Giusti, PhD4*, Luciana Rossi, PhD4*, Giovanni Martinelli, MD3*, Rossella Manfredini, MD2*, Alberto Bosi, MD1* and Alessandro M. Vannucchi, MD1

1Hematology, Universitá degli Studi di Firenze, Firenze, Italy
2Biomedical Sciences, Università di Modena eReggio Emilia, Modena, Italy
3Department of Hematology and Oncological Sciences, Seragnoli Institute, University of Bologna, Bologna, Italy
4Centre for Thrombosis, Universitá degli Studi di Firenze, Firenze, Italy

Efficacy of R723, a Potent and Selective JAK2 Inhibitor, in JAK2 V617F-Induced Murine MPD Model

Kotaro Shide1, Takuro Kameda1*, Vadim Markovtsov2*, Takuya Matsunaga1*, Haruko Shimoda1*, Tomonori Hidaka1*, Keiko Katayose1*, Yoko Kubuki1*, Somasekhar Bhamidipati3*, Gary Park2*, Allan Torneros4*, Matt Duan2*, Yasumichi Hitoshi4 and Kazuya Shimoda1

1Gastroenterology and Hematology, Department of Internal Medicine, Faculty of Medicine, Miyazaki University, Miyazaki, Japan
2Oncology, Rigel Pharmaceuticals, South San Francisco, CA
3Chemistry, Rigel Pharmaceuticals, South San Francico, CA
4Rigel Pharmaceuticals, South San Francisco, CA

Efficacy of the Novel Non-Quinone Based HSP-90 Inhibitor PU-H71 in JAK2V617F and MPLW515L-Induced Murine Models of Myeloproliferative Neoplasms

Priya Koppikar, PhD1*, Sachie Marubayashi2*, Tony Taldone3*, Omar Abdel-Wahab4*, Nathan West5*, Alexander Gozman6*, James Ahn7*, Anna Rodina7*, Neha Bhagwat8*, Cyrus V. Hedvat, MD, PhD2, James E. Bradner, MD9, Gabriela Chiosis10* and Ross L. Levine, MD2

1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
2Memorial Sloan-Kettering Cancer Center, New York, NY
3Pharmacology, Memorial Sloan-Kettering Cancer Center, New York
4Hematology and Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
5Chemical Biology, Broad Institute of Harvard, MIT, Boston, MA
6Memorial Sloan Kettering Cancer Center, New York, NY
7Pharmacology, Memorial Sloan-Kettering Cancer Center, New York, NY
8Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY
9Broad Institute of Harvard and MIT, Boston, MA
10Molecular Pharmacology & Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY

Erythroblasts From Polycythemia Vera Patients Express the Dominant negative β Isoform of the Glucocorticoid Receptor

Lilian Varricchio, Ph.D1*, Antonella Di Noia2*, Elena Alfani, Ph.D2*, Emilia Stellacci, Ph.D3*, Angela Battistini, Ph.D3*, Angela di Baldassarre, Ph.D4*, Giovanni Migliaccio, Ph.D.2, Alessandro M. Vannucchi, MD5, Damiano Rondelli, MD6*, Ronald Hoffman, MD1 and Anna Rita Migliaccio, Ph.D.1

1Tisch Cancer Institute and Myeloproliferative Disease Research Consortium, Mount Sinai School of Medicine, New York, NY
2Cell Biology and Neuroscience, Istituto Superiore di Sanita', Rome, Italy
3Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanita', Rome, Italy
4Biomorphology, University of Chieti, Chieti, Italy
5Hematology, Universitá degli Studi di Firenze, Firenze, Italy
6Univ. of Illinois at Chicago, Hematology/Oncology, Dept of Medicine, Chicago, IL

Establishment of Mouse PMF Model by the Introduction of Constitutive STAT5a Into Purified Hematopoietic Stem Cells

Takafumi Shimizu1*, Akihiko Ito2*, Akira Nakagawa1*, Toshinobu Nishimura1*, Satoshi Yamazaki1*, Shoichi Iriguchi1*, Shin Kaneko1* and Hiromitsu Nakauchi1

1Division of Stem Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
2Pathology Core Laboratory Section 1, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Generation and Characterization of Transgenic Mice Expressing MplW515L

Wanming Zhao1*, Shu Xing1*, Rufei Gao1*, Aref Al-Kali, MD2, Wanting Tina Ho1* and Zhizhuang Joe Zhao, Ph.D1

1Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
2Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Genetic and Pharmacologic Targeting of STAT5/Gab2/PI3K/mTOR Signaling in a Mouse Myeloproliferative Disease Model

Geqiang Li, Ph.D.1*, Zhengqi Wang, Ph.D.1, Kristy L. Miskimen, Ph.D.1*, Xiu Yan Xie, M.D.2*, William Tse, M.D.3*, Fabrice Gouilleux, Ph.D.4*, Richard Moriggl, Ph.D.5* and Kevin D. Bunting, Ph.D.1

1Department of Medicine - Hematology/Oncology, Case Western Reserve University, Cleveland, OH
2Department of Pathology, Summa Health Barberton Hospital, Barberton
3Department of Medicine - Hematology/Oncology, University of Colorado, Aurora, CO
4Immunology, Inserm U925, Amiens, France
5Ludwig Boltzman Institute for Cancer Research, Vienna, Austria

Hypereosinophilia in 357 Consecutive Patients: Disease Spectrum and Clinical and Laboratory Correlates

Ken-Hong Lim, MD1*, Ayalew Tefferi, MD2, Chin Yang Li, MD3* and Animesh D. Pardanani, MBBS, PhD2

1Mackay Memorial Hospital, Taipei, Taiwan
2Hematology, Mayo Clinic, Rochester, MN
3Hematopathology, Mayo Clinic, Rochester, MN

Molecular and Clinical Features of the Myeloproliferative Neoplasm Associated with JAK2 Exon 12 Mutations: a European Multicenter Study

Francesco Passamonti1*, Susanne Schnittger2, François Girodon3*, Jean-Jacques Kiladjian4*, Mary Frances McMullin5*, Marco Ruggeri6*, Eric Lippert7*, Alessandro Vannucchi8*, Carles Besses9*, Elisa Rumi1*, Chiara Elena1*, Torsten Haferlach2, Cristiana Pascutto1* and Mario Cazzola1

1Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
2MLL Munich Leukemia Laboratory, Munich, Germany
3Laboratoire d'Hématologie, Hôpital du Bocage, Centre Hospitalier Universitaire, Dijon, France
4Clinical Investigation Center, Hôpital Saint-Louis, Paris, France
5Haematology, Centre for Cancer Research and Cell Biology, The Queen's University Belfast, Belfast, United Kingdom
6Hematology, San Bortolo Hospital, Vicenza, Italy
7Laboratoire d'Hématologie, Centre Hospitalier Universitaire, Bordeaux, France
8Department of Hematology, University of Florence, Florence, Italy
9Department of Clinical Hematology, Hospital del Mar-IMIM, Barcelona, Spain

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis

Srdan Verstovsek, MD, PhD1, Olatoyosi Odenike, MD2, Bart Scott, MD3, Zeev Estrov, MD1, Jorge Cortes, MD1, Deborah A. Thomas, MD1, Jeanette Wood, PhD4*, Kantharaj Ethirajulu, PhD4*, Ann Lowe, MD4*, Huan J. Zhu, MD, PhD4, Hagop Kantarjian, MD1 and H. Joachim Deeg, MD3

1Department of Leukemia, University of Texas, M.D. Anderson Cancer Center, Houston, TX
2University of Chicago, Chicago, IL
3Fred Hutchinson Cancer Research Center, Seattle, WA
4S*BIO PTE LTD, Singapore, Singapore

Platelet Antiaggregant Therapy Prevents Venous Thrombosis in Patients with JAK2 V617F Positive Essential Thrombocythemia without Indication of Cytoreductive Treatment

Alberto Alvarez-Larrán1*, Francisco Cervantes2*, Eduardo Arellano-Rodrigo3, Virginia Pérez-Andreu4*, Juan-Carlos Hernández-Boluda5*, Carlos Salvador6*, Ramón Ayats7*, Anna Muntañola8*, Beatriz Bellosillo1*, Vicente Vicente4*, Carmen Burgaleta9*, Anna Gaya2*, Luis Hernández-Nieto10*, Blanca Xicoy11* and Carlos Besses1*

1Hematology Department, Hospital del Mar, Barcelona, Spain
2Hematology Department, Hospital Clinic, Barcelona, Spain
3Hemostasis & Thrombosis, Hospital General Vall d'Hebron, Barcelona, Spain
4Hematology Department, Hospital Morales Messeguer, Murcia, Spain
5Hematology Department, Hospital Clínico, Valencia, Spain
6Hematology Department, Hospital Miguel Servet, Zaragoza, Spain
7Hematology Department, Hospital Sant Pau, Spain
8Hematology Department, Mutua de Terrassa, Terrassa, Spain
9Hematology Department, Hospital Príncipe de Asturias, Madrid, Spain
10Hematology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
11Hematology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

Plitidepsin Inhibits the Growth of Cells Harboring JAK2V617F Mutation

Costanza Bogani, PhD1*, Paola Guglielmelli, MD1*, Niccolò Bartalucci, BSc1*, Miguel Aracil, MD2*, Maria Fe Paz, PhD2*, Alberto Bosi, MD1* and Alessandro M. Vannucchi, MD1

1Hematology, Universitá degli Studi di Firenze, Firenze, Italy
2PharmaMar, Colmenar Viejo, Madrid, Spain

Polycythemia Vera with Multiple Clones Carrying Different Mutations (L611V, V617F, L611V/V617F) in Exon 14 of JAK2

Cédric Cleyrat1*, Jaroslav Jelinek2, François Girodon3*, Marjorie Boissinot1*, Thierry Ponge4*, Jean-Luc Harousseau5*, Jean-Pierre Issa2*, Sylvie Hermouet1 and Sylvie Hermouet6*

1INSERM U892, Centre de Recherche en Cancérologie Nantes/Angers, IRT1, Nantes, France
2Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX
3Laboratoire d'Hématologie, Hôpital du Bocage, Centre Hospitalier Universitaire, Dijon, France
4Medecine Interne, Centre Hospitalier Universitaire, Nantes, France
5Laboratoire d'hématologie, Centre hospitalier universitaire, Nantes, France
6Laboratoire d'hématologie, Institut de biologie, centre hospitalier universitaire, Nantes, France

Rho Kinase Inhibitors as Potential Therapeutic Agents for Oncogenic KIT, FLT3, and BCR-ABL Induced Leukemogenesis

Raghuveer Mali, Ph.D.1*, Baskar Ramdas, Ph.D.2*, Veerendra Munugalavadla1*, Emily Sims1* and Reuben Kapur, PhD3

1Pediatrics, Indiana University School of Medicine, Herman B Wells Center for Pediatric Research, Indianapolis, IN
2Pediatrics, Indiana University School of Medicine, Indianapolis, IN
3Indiana Univ. School of Med., Indianapolis, IN

Screening for MPL mutations in Essential Thrombocythemia and Primary Myelofibrosis: Normal Mpl Expression and Absence of Constitutive STAT3 and STAT5 Activation in MPLW515L-Positive Platelets

Laura Korin, M.D.*, Ana C Glembotsky*, Paola R Lev, Ph.D.*, Carlos D Chazarreta*, Rosana F Marta, Ph.D.*, Felisa C. Molinas, MD, PhD and Paula Graciela Heller, M.D., Ph.D*

Hematologia Investigacion, IDIM Alfredo Lanari, Buenos Aires, Argentina

Survival of  Myeloid Malignancies in EUROPE: Results of the HAEMACARE Project

Marc Maynadié, MD, PhD1, Roberta De Angelis2*, Claudia Allemani3*, Riccardo Capocaccia2*, Jean Michel Lutz4*, Rafael Marcos Gragera5*, Carmen Tereanu3*, Otto Visser, MD6 and Milena Sant3*

1Registre des Hémopathies Malignes de Côte d'Or, EA4184, University of Burgundy, Dijon cedex, France
2Cancer Epidemiology, National Centre for Epidemiology, surveillance and Health Promotion, Rome, Italy
3Department of preventive and predictive Medicine, Fondazione IRCCS"Istituto Nazionale dei Tumori, Milan, Italy
4National Institute for Cancer Epidemiology and Registration, Zurich, Switzerland
5Girona Cancer Registry, Girona, Spain
6Hematology, VU-University Medical Center, Amsterdam, Netherlands

TET2 Mutations in a Cohort of Patients with Myeloproliferative Neoplasms Lacking a Molecular Marker

Luz Maria Martinez-Aviles1*, Carlos Besses2*, Alberto Alvarez-Larran3*, Aina Pons4*, Sergi Serrano5* and Beatriz Bellosillo2*

1Pathology, Hospital del Mar-IMAS, Barcelona, Spain
2Hematology Department, Hospital del Mar, Barcelona, Spain
3Hematologia, Hospital del Mar, Barcelona, Spain
4Grup de Recerca Aplicada en Neoplasies Hematològiques, IMIM- Hospital del Mar, Barcelona, Spain
5Pathology Department, Hospital del Mar, Barcelona, Spain

TET2 Mutations in Polycythemia Vera (PV) in Some Cases Follow Rather Than Precede JAK2 V617F Mutation, Are Not a Disease-Initiating Event, Affect Mainly Erythropoiesis, and Contribute to Increased Aggressivity of PV Clone

Sabina Swierczek*, PhD1*, Christine Bellanne-Chantelot2*, Donghoon Yoon, PhD3, Cecile Saint-Martin2*, Soo Jin Kim4*, Albert Najman, MD5 and Josef T. Prchal, MD6

1Medicine, University of Utah, Salt Lake City, UT
2Department of Genetics, AP-HP Pitié-Salpétriére, Paris, France
3Hematology Div., University of Utah, Salt Lake City, UT
4Hematology Div., University of Utah, Slc
5Hematology, St. Antoine Hospital, Paris, France
6University of Utah, Salt Lake City, UT

The Marine Tunicate-Derived Cyclic Depsipeptide Aplidin Restores Functional Hematopoiesis in the Marrow of the Gata1low Mouse Model of Myelofibrosis

Maria Verrucci, Ph.D1*, Alessandro Pancrazzi, PhD2*, Fabrizio Martelli, Ph.D3*, Paola Guglielminelli2*, Miguel Aracil4*, Maria Zingariello, Ph.D5*, Emanuela D'Amore3*, Jose Jimeno4*, Alessandro M. Vannucchi, MD6 and Anna Rita Migliaccio, Ph.D.7*

1Istituto Superiore di Sanità, Biologia Cellulare, Rome, Italy
2Hematology, Università  degli Studi di Firenze, Firenze, Italy
3Biologia Cellulare, Istituto Superiore di Sanità, Rome, Italy
4Pharmamar, Colmenar Viejo, Madrid, Spain
5Biomorofologia, Università G. D'Annunzio, Chieti, Italy
6Hematology, Universitá degli Studi di Firenze, Firenze, Italy
7Tisch Cancer Institute and Myeloproliferative Disease Research Consortium, Mount Sinai School of Medicine, New York, NY

Thrombotic Events in Primary Myelofibrosis: Prevalence and Prognostic Factors in 207 Consecutive Patients

Michelle Elliott, MB, BCh1*, Terra Lasho2*, Christy Finke, BS1*, Animesh D. Pardanani, MBBS, PhD3 and Ayalew Tefferi, MD3

1Mayo Clinic, Rochester, MN
2Medicine, Mayo Clinic, Rochester
3Hematology, Mayo Clinic, Rochester, MN

Treatment with Pegylated Interferon Alpha 2a in Combination with the Bcl-Xl Inhibitor ABT-737 Specifically Targets JAK2V617F Positive Hematopoietic  Progenitor Cells From Patients with Polycythemia Vera

Min Lu, PhD, Wei Zhang*, Daniel Yoo*, Dmitriy Berenzon*, Yan Li*, Xiaoli Wang, MD, PhD, Adam Austin*, John Mascarenhas, MD, Mingjiang Xu, MD, PhD and Ronald Hoffman, MD

Medicine, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY

Validation of the Serial Use of the Myelofibrosis Symptom Assessment Form (MF-SAF)  for Measuring Symptomatic Improvement:  Performance in 86 Myelofibrosis Patients On INCB018424 Clinical Trial

Ruben A. Mesa, MD1, Hagop Kantarjian2*, Ayalew Tefferi, MD3, Richard Levy, MD4*, Kris Vaddi5*, Susan Erickson-Viitanen, PhD6*, Deborah A. Thomas, MD7, Jorge Cortes-Franco, MD8*, Gautam Borthakur, MBBS9*, Animesh D. Pardanani, MBBS, PhD3, Zeev Estrov, MD10 and Srdan Verstovsek, MD, PhD11

1Mayo Clinic, Scottsdale, AZ
2M.D. Anderson Cancer Center, Houston, TX
3Hematology, Mayo Clinic, Rochester, MN
4Incyte, Wilmington, DE
5Incyte Corporation, Wilmington, DE
6Incyte Co., Wilmington, DE
7Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX
8Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX
9Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
10Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
11Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX

Weight Loss, Splenomegaly, and Hypocholesterolemia in Myeloproliferative Neoplasms: Patterns and Relevance from the Pre JAK2 Inhibitor Era

Ruben A. Mesa, MD1, Susan Schwager2*, Jocelin Huang, MD3*, Animesh D. Pardanani, MBBS, PhD3, Kebede Hussein, MD4, John Camoriano, MD1 and Ayalew Tefferi, MD3

1Mayo Clinic, Scottsdale, AZ
2Mayo Clinic, Rochester, MN
3Hematology, Mayo Clinic, Rochester, MN
4Internal Medicine, Mayo Clinic, Rochester, MN

*signifies non-member of ASH